Parameter
| Biomarker | Enhanced Liver Fibrosis Testing (ELF™) | Full name | Enhanced Liver Fibrosis Testing | Molecular Type | Composite indicators (hyaluronic acid, procollagen type III N-terminal peptide, tissue inhibitor of metalloproteinase-1) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Staging and prognosis of liver fibrosis | ||
| Disease | Viral Hepatitis | Disease Subtypes | / | ||
| Organ | Liver | Test Sample / Technology Platform | Serum | ||
| Pathobiological Mechanisms | Based on the molecular markers related to liver fibrosis, it directly reflects the degree of liver fibrosis activity. It can predict the risk of complications of liver cirrhosis (such as variceal bleeding) and liver cancer | ||||
| Clinical Availability Status | Clinical research phase (used in clinical practice in some areas) | ||||
| Notes and Dynamics | Compared with FIB-4, it reflects fibrosis activity more accurately and is suitable for fibrosis staging of chronic liver diseases (such as MASLD and chronic hepatitis B). However, its high detection cost limits its large-scale popularization | ||||